Dr. Lal Path Labs Ltd. (LALPATHLAB) — Related Party Transaction | 19 August 2026

19 August 2026 · NSE 🟡 Notable Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Incorporation of Tashkent subsidiary with 70% stake subscribed by Dubai entity

🔄 What Changed

Establishment of new diagnostic subsidiary in Uzbekistan

🔮 What's Next

Not Applicable

💡 Investor Takeaway

The move expands the company's geographic footprint into Central Asia through a newly created diagnostic entity.

Dr Lal PathLabs announced incorporation of Dr Lal PathLabs Indomed LLC in Tashkent, Uzbekistan, with its Dubai subsidiary subscribing 70% of the new entity's share capital at face value. The subsidiary will operate in diagnostic services to expand the group's presence in Central Asia. The filing confirms regulatory compliance under SEBI Listing Regulations and includes details of the step-down structure and initial business focus.

📄 View Original Announcement (PDF)

📊 Stock Analysis — LALPATHLAB ✨ Ask AI About This

About Dr. Lal Path Labs Ltd. (LALPATHLAB)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹33,319.68 CrP/E: 61.0ROE: 21.6%ROCE: 29.6%Div Yield: 1.23%

View full LALPATHLAB stock details →

📡 Get AI alerts when LALPATHLAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LALPATHLAB — Free

💡 Ask AI about this filing

"What is the valuation of the new Tashkent subsidiary?""How does this affect Dr Lal PathLabs' Central Asia growth strategy?""What are the expected revenue contributions from Uzbekistan operations?"

Ask AI Free →

📊 More LALPATHLAB filings

🔴 Corporate Action — 1 October 2026Dr Lal Pathlabs announced completion of its acquisition of SN Genelab Private Limited on October 1, ...
🔴 Corporate Action — 26 September 2026Dr Lal PathLabs announced completion of its Dubai subsidiary's acquisition of an 80% stake in Sunshi...
🟡 Board Meeting — 25 September 2026The board announced a meeting on November 4, 2026 to approve unaudited standalone and consolidated f...
Announcement — 25 September 2026Dr Lal Pathlabs announced a board meeting on November 4, 2026, to approve Q3 and H1 FY27 financial r...
🟡 Board Meeting — 24 September 2026Dr Lal Pathlabs announced on September 24, 2026, that its board approved acquiring a 70% stake in SN...

See all LALPATHLAB filings →

🔥 Also filed on 19 August 2026

GOCOLORSGo Fashion (India) LimitedAnnual Report OILOil India LimitedCorporate Action GLAXOGlaxoSmithKline Pharmaceuticals LimitedFinancial Results TILTIL LimitedFinancial Results SETUINFRASetubandhan Infrastructure LimitedFinancial Results ASALCBRAssociated Alcohols & Breweries Ltd.Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LALPATHLAB files new disclosures

Track LALPATHLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.